• Cognitive Geology

  Participated · Equity · Oct 2017

  Cognitive Geology is an Edinburgh-based provider of petroleum geoscience software, founded in 2014 by geologist Luke Johnson. Its products target onshore and offshore conventional and unconventional oil & gas reservoirs. The company recently launched Hutton, an advanced geological data analysis tool that plugs into major industry platforms including Petrel™ and JewelSuite™ to extract progressive trends from complex datasets. Cognitive Geology raised £2m in funding and intends to use the proceeds to grow the business, roll out its software to oil companies, and further develop its pipeline of advanced third‑generation petroleum geoscience modules. The company positions its tools to help geologists make informed decisions throughout the life cycle of a reservoir.

• NeuroVia

  Participated · Series A · Jul 2017

  NeuroVia is developing NV1205, a small-molecule therapeutic intended as a disease-modifying treatment for X-ALD. The company plans to use the Series A proceeds to advance NV1205 into a clinical proof-of-concept development program in X-ALD. Preclinical studies in an ABCD1-deficient mouse model showed NV1205 reduced very long chain fatty acids (VLCFAs) in brain, adrenal tissue and blood; those results were published in the journal Endocrinology. There are currently only two available treatments for childhood cerebral X-ALD—Lorenzo's Oil and stem cell transplantation—and both have significant limitations, leaving an unmet medical need. NeuroVia is positioning NV1205 as a novel pharmaceutical option for patients across X-ALD phenotypes. The company closed a $14 million Series A financing to support these development activities.

• UltraSoC Technologies

  Participated · Equity · May 2017

  UltraSoC develops embedded analytics and monitoring technology delivered as semiconductor IP and software for systems-on-chip that power consumer electronics, computing and communications products. Its technology enables product designers to add cybersecurity, functional safety and performance-tuning features. The company counts customers including Seagate, C-SKY, Esperanto, Kraftway and Microchip. UltraSoC closed a £5m equity funding round to support growth and product development. The funds will be used to recruit hardware and software engineers at its Cambridge headquarters and Bristol design centre, open an engineering centre in Warsaw to develop data‑science and machine‑learning capabilities, expand its customer support engineering network globally, and increase commercial presence in key markets including Europe, the USA, Japan and China. The business is led by Chairman Alberto Sangiovanni-Vincentelli and CEO Rupert Baines. UltraSoC provides a suite of semiconductor IP that enables chip designers to integrate an intelligent analytics infrastructure directly into device hardware. Its embedded analytics monitor and analyze real-world system behavior to reduce power consumption, increase performance, protect against malicious intrusions, and ensure product safety. The company serves a broad range of markets including automotive, IoT, at-scale computing and communications. Customers using its technology include HiSilicon (Huawei), Imagination Technologies, Movidius (now Intel), and Microsemi. Led by CEO Rupert Baines and based in Cambridge, UK, UltraSoC completed a £5m ($6.4m) funding round and plans to use the proceeds to continue deployment of its technology and realize its vision of embedding intelligent analytics capabilities into every chip. UltraSoC Technologies develops UltraDebug, an advanced on-chip debugging and monitoring technology for multiple-processor embedded systems used in applications from automotive to mobile phones. The product is designed to debug the application software that provides functionality and performance in modern electronic systems. The company positions its technology as addressing gaps left by incumbent debugging solutions as devices shrink and gain complexity. UltraSoC plans to develop the technology platform into a licensable product and to expand its technical and marketing capability in Cambridge. Financially, the company raised a £2m investment from Octopus Ventures in 2010 and previously closed a £400,000 seed round in 2009 from the South East Seed Fund and Iceni Seedcorn Fund. UltraSoC was founded in 2006 by Dr Karl Heeks and Professor Klaus McDonald-Maier and was spun out from the Universities of Kent and Essex in 2008.

• Cavion

  Led · Series A · Jan 2017

  Cavion, headquartered in Charlottesville, Va., is a clinical-stage biotechnology company focused on developing T-type calcium channel (Cav3) modulators for neurological diseases and oncologic indications. Its lead program is the Cav3 inhibitor CX-8998, which Cavion plans to evaluate in a proof-of-concept Phase 2 study in Essential Tremor later this year. The company is also developing additional new chemical entities that inhibit the Cav3 channel for application across multiple therapeutic areas. Cavion is co-sponsoring a Phase 1 trial of mibefradil combined with hypofractionated radiation therapy for recurrent glioblastoma multiforme with the Yale University Comprehensive Cancer Center. The company recently completed a $26.1 million Series A venture financing co-led by Lilly Ventures and Novartis Venture Fund with participation from Enso Ventures and existing investors.

• Galera Therapeutics

  Participated · Series B · Nov 2016

  Founded in 2009, Galera Therapeutics develops small-molecule dismutase mimetics that replicate the body’s superoxide dismutase enzymes. In pre-clinical models these compounds simultaneously attack tumors and protect healthy tissue from damage caused by radiation therapy, chemotherapy, and cytokine immunotherapies. The company’s lead program targets prevention of oral mucositis, a debilitating side effect of cancer therapy, and is positioned to move directly into Phase 2a human proof-of-concept studies thanks to extensive prior clinical experience in non-cancer indications. Beyond oral mucositis, Galera intends to leverage its proprietary platform to address additional side effects of cancer treatment. The team is led by inventor Dennis Riley, Ph.D., and includes experienced executives and drug developers. Financially, the company has secured a Series “1” financing of undisclosed size to fund its lead program and platform expansion; no revenue or user metrics were provided in the article.

No current team members are available.